Core Viewpoint - Rosen Law Firm is reminding investors who purchased Treace Medical Concepts, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Treace Medical securities is from May 8, 2023, to May 7, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 10, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors [3] Group 3: Case Allegations - The lawsuit alleges that Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [4] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [4] - The lawsuit asserts that the positive statements made by the defendants about the company's business and prospects were materially misleading [4]

Core Viewpoint - A securities class action lawsuit has been filed against Open Lending Corporation for misrepresentation and failure to disclose significant financial issues during the Class Period from February 24, 2022, to March 31, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Open Lending securities during the specified Class Period [1][2]. - Investors have until June 30, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against the Company - The complaint alleges that Open Lending misrepresented its risk-based pricing models and profit share revenue [3]. - It is claimed that the company failed to disclose that its 2021 and 2022 vintage loans were worth significantly less than their outstanding balances [3]. - The underperformance of the company's 2023 and 2024 vintage loans was also misrepresented [3]. Group 3: Financial Impact and Company Response - On March 17, 2025, Open Lending announced it would delay its Annual Report for 2024, leading to a 9% drop in share price to $3.91 [4]. - The company reported a quarterly revenue of negative $56.9 million for Q4 2024, attributed to an $81.3 million reduction in estimated profit share revenues due to heightened delinquencies and defaults [5]. - Open Lending identified three factors contributing to the reduction in estimated profit share: deterioration of 2021 and 2022 vintages, underperformance of 2023 and 2024 vintages, and continued elevated delinquencies [5]. - Following the financial disclosure, the share price plummeted 57% to $1.17 on April 1, 2025 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to significant declines in revenue and misleading statements made by the company regarding its business operations and prospects [2][4]. Financial Performance - Iovance reported a quarterly total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a substantial decline [5]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [5]. Legal Proceedings - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Iovance made materially false and misleading statements and failed to disclose adverse facts about its business, including issues with new Authorized Treatment Centers (ATCs) and patient treatment timelines [4]. Market Reaction - Following the release of the disappointing financial results, Iovance's share price fell by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, with unusually high trading volume [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Ibotta, Inc. due to alleged violations of federal securities laws related to misleading statements about its contract with Kroger and subsequent financial performance, leading to significant investor losses. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $100,000 in Ibotta to contact them for legal options [1] - The firm is investigating claims against Ibotta and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [3] - The complaint alleges that Ibotta and its executives made false statements and failed to disclose risks regarding their at-will contract with Kroger, which could be canceled without warning [5] Group 2: Financial Performance and Stock Impact - Ibotta conducted its IPO on April 13, 2024, offering 6.6 million shares at $88.00 each [6] - On August 13, 2024, Ibotta reported a net loss of $34.0 million for Q2 2024, with operating expenses more than doubling year-over-year, and provided a revenue forecast below consensus estimates [7] - Following the Q2 report, Ibotta's stock dropped by $15.53 per share, or 26%, closing at $42.66 on August 14, 2024 [8] - On February 26, 2025, Ibotta's shares fell by $29.08 per share, or 46%, closing at $34.01 after reporting Q4 earnings that missed expectations and provided weak guidance for Q1 2025 [8]